- Home
- IHRT vs MRVI Comparison
IHRT vs MRVI Comparison
Compare IHRT & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHRT
- MRVI
- Stock Information
- Founded
- IHRT 1974
- MRVI 2014
- Country
- IHRT United States
- MRVI United States
- Employees
- IHRT N/A
- MRVI N/A
- Industry
- IHRT Broadcasting
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- IHRT Consumer Discretionary
- MRVI Health Care
- Exchange
- IHRT Nasdaq
- MRVI Nasdaq
- Market Cap
- IHRT N/A
- MRVI 262.9M
- IPO Year
- IHRT 2019
- MRVI 2020
- Fundamental
- Price
- IHRT $1.21
- MRVI $2.07
- Analyst Decision
- IHRT Buy
- MRVI Hold
- Analyst Count
- IHRT 3
- MRVI 9
- Target Price
- IHRT $2.83
- MRVI $6.54
- AVG Volume (30 Days)
- IHRT 598.4K
- MRVI 1.7M
- Earning Date
- IHRT 05-12-2025
- MRVI 05-12-2025
- Dividend Yield
- IHRT N/A
- MRVI N/A
- EPS Growth
- IHRT N/A
- MRVI N/A
- EPS
- IHRT N/A
- MRVI N/A
- Revenue
- IHRT $3,854,532,000.00
- MRVI $259,185,000.00
- Revenue This Year
- IHRT $0.97
- MRVI N/A
- Revenue Next Year
- IHRT $5.09
- MRVI $14.23
- P/E Ratio
- IHRT N/A
- MRVI N/A
- Revenue Growth
- IHRT 2.76
- MRVI N/A
- 52 Week Low
- IHRT $0.81
- MRVI $1.67
- 52 Week High
- IHRT $2.84
- MRVI $11.56
- Technical
- Relative Strength Index (RSI)
- IHRT 51.94
- MRVI 47.53
- Support Level
- IHRT $1.02
- MRVI $1.96
- Resistance Level
- IHRT $1.09
- MRVI $2.20
- Average True Range (ATR)
- IHRT 0.08
- MRVI 0.12
- MACD
- IHRT 0.04
- MRVI 0.05
- Stochastic Oscillator
- IHRT 86.67
- MRVI 73.27
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.